الفهرس 
ContentsOnly 14 pages are availabe for public view
 |  | from | 32 |  |  |
| | | from | 32 | | |
Abstract
Introduction Autoimmune cytopenia (AIC) has been reported since 1960s as a common complication of chronic lymphocytic leukemia (CLL). AIC can be in many clinical forms: autoimmune hemolytic anemia (AIHA), Immune thrombocytopenia (ITP), Evan syndrome, pure red cell aplasia (PRCA), autoimmune granulocytopenia (AIG). Aim of the work To our knowledge, there are no studies of the prevalence of AIC in CLL in our locality. So we aimed to study the prevalence, clinical associations and prognostic significance of AIC among a sample of patients attending the hematology unit in the Oncology Center in Mansoura University (OCMU). Patients and Methods After collecting, reviewing the OCMU database: the patients (101 cases) were classified according to the Binet system into 3 stages and the stage C patients were subdivided into 3 subgroups according to the etiology of cytopenia (whether infiltrative or immune or both together). The data of the enrolled subjects were recollected again after 1 year from diagnosis and/or treatment to re-evaluate their clinical condition and response. Results : In this study, we reported 11.8% as a prevalence of AIC among our CLL sample with a prevalence of 6.9%, 3% and 7.9% for AIHA, ITP and Evan respectively. PRCA and AIG were not reported. The immune group at diagnosis showed less organomegally, higher serum markers (LDH, B2 microglobulin) and higher number of positive cases harboring positive CD38 and ZAP70) than the infiltrative group. However, after 1 year their clinical and laboratory response was unsatisfactory in comparison to the other groups. However, no significant difference in the overall survival was found. Conclusion AIC is a fingerprint of a biologically more aggressive disease even with no significant impact on OS.